- Home
- PRQR
as 04-01-2025 4:00pm EST
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
| Founded: | 2012 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 309.5M | IPO Year: | 2014 |
| Target Price: | $8.50 | AVG Volume (30 days): | 745.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $4.62 | Next Earning Date: | 03-13-2025 |
| Revenue: | $20,235,014 | Revenue Growth: | 196.41% |
| Revenue Growth (this year): | 39.44% | Revenue Growth (next year): | -60.33% |
Latest ProQR Therapeutics N.V. News
PRQR Breaking Stock News: Dive into PRQR Ticker-Specific Updates for Smart Investing
Simply Wall St.
19 days ago
ProQR Therapeutics Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
20 days ago
ProQR Announces Year End 2024 Operating and Financial Results
MT Newswires
23 days ago
Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4
Simply Wall St.
2 months ago
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%
Simply Wall St.
3 months ago
Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?
TipRanks
4 months ago
ProQR Therapeutics announces $8.1M in new funding from RSRT
GlobeNewswire
4 months ago
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
GlobeNewswire
4 months ago
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
Compare PRQR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.